Company Profile For Jerini AG

Jerini AG is a Germany-based company, operating in the pharmaceutical sector. Its focus is on the discovery, development and commercialization of peptide-based services and drugs to treat diseases with limited or no treatment options. The Company’s research and development pipeline includes products from such areas as ophthalmology, oncology, inflammation diseases, hereditary angioedema and others. Its main product, Firazyr, is used for the treatment of hereditary angioedema (HAE). As at December 31, 2008, the Company operated through eight subsidiaries including Jerini US, Inc. in the United States, JPT Peptide Technologies GmbH (JPT) in Germany and Jerini Trading Ltd. on Malta, among others.

BRIEF: For the nine months ended 30 September 2009, Jerini AG's total revenue increased 79% to EUR6.1M. Net loss for the period from continuing operations decreased 1% to EUR29.6M. Total revenue reflects favourable market conditions as well as an increase in demand for the Company's products and services. Lower net loss for the period from continuing operations reflects higher operating margins.